State Street Corporation reported beneficial ownership of 3,116,804 shares of Protagonist Therapeutics Inc. The filing, a Schedule 13G, shows 4.9% of the class and discloses shared voting power of 2,956,605 and shared dispositive power of 3,116,804. The filing lists related State Street entities and was signed by a Senior Vice President on 05/12/2026.
Positive
None.
Negative
None.
Insights
Large passive holder disclosure: State Street reports a 4.9% stake in Protagonist.
Schedule 13G filings typically reflect passive or investment-manager holdings; this filing lists 3,116,804 shares and 2,956,605 shared voting power. The filing names multiple State Street entities as holders and shows shared dispositive authority.
Impact depends on whether holdings are managed actively or passively; subsequent filings (amendments or a Form 13D) would indicate an active intent. Cash‑flow treatment and trading intentions are not specified in the excerpt.
Key Figures
Beneficial ownership:3,116,804 sharesPercent of class:4.9%Shared voting power:2,956,605 shares+2 more
5 metrics
Beneficial ownership3,116,804 sharesAmount beneficially owned as reported
Percent of class4.9%Percent of class reported on Schedule 13G
Shared voting power2,956,605 sharesShared power to vote or direct the vote
Filing typeSchedule 13GForm used to report passive beneficial ownership
As-of date03/31/2026Ownership snapshot date in header
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerregulatory
"(iv) Shared power to dispose or to direct the disposition of: 3,116,804"
Schedule 13Gregulatory
"CONTENT METADATA: "form_type": "SCHEDULE 13G""
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
What stake does State Street hold in Protagonist Therapeutics (PTGX)?
State Street beneficially owns 3,116,804 shares, representing 4.9% of the class. The Schedule 13G lists shared voting power of 2,956,605 and shared dispositive power of 3,116,804 as reported in the filing.
Does the Schedule 13G indicate active control by State Street over PTGX?
The filing indicates shared voting and dispositive power but does not claim control. Schedule 13G filings generally signal passive/investment manager holdings; the excerpt does not state active control or an intent to influence management.
Which State Street entities are listed as holders in the filing?
The filing names several entities, including SSGA Funds Management, Inc., State Street Bank and Trust Company, and State Street Global Advisors affiliates. These entities are reported as the relevant subsidiaries or investment-adviser vehicles.
When was the Schedule 13G signed and filed for PTGX?
The signature block shows the filing was signed by Elizabeth Schaefer, Senior Vice President on 05/12/2026. The header references an ownership snapshot as of 03/31/2026.
Does this filing show the number of shares State Street can sell immediately?
The filing reports beneficial ownership and dispositive power (3,116,804 shares) but does not specify trading plans, sale timing, or immediate sellable amounts. No cash‑flow or disposition schedule is disclosed in the excerpt.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
PROTAGONIST THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
74366E102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
74366E102
1
Names of Reporting Persons
STATE STREET CORPORATION
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MASSACHUSETTS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,956,605.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,116,804.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,116,804.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.9 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PROTAGONIST THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
7707 GATEWAY BLVD SUITE 140, NEWARK, CALIFORNIA, 94560
Item 2.
(a)
Name of person filing:
STATE STREET CORPORATION;
(b)
Address or principal business office or, if none, residence:
ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)
Citizenship:
MA
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP Number(s):
74366E102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
3116804.00
(b)
Percent of class:
4.9 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
2,956,605
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
3,116,804
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
NOT APPLICABLE
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET BANK AND TRUST COMPANY (BK);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
NOT APPLICABLE
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
NOT APPLICABLE
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
